Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02375451 · ClinicalTrials.gov registry record
Effect of Childhood Radioiodine Therapy on Salivary Function
A clinical trial of Thyroid Cancer and Xerostomia, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT02375451 is a study of Thyroid Cancer and Xerostomia that has completed, run by Boston Children's Hospital. The registered enrollment target is 70 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02375451, a study of Thyroid Cancer and Xerostomia, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Radioiodine (I-131) therapy for thyroid disease is known to decrease salivary function in adult patients. The impact of pediatric I-131 exposure on salivary function is unknown. The investigators goals are to answer this question by measuring salivary gland function before and after I-131 administration in children who receive radioiodine therapy at our hospital for thyroid disease.
Conditions Studied
Interventions
- OTHER Radioiodine
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02375451
The ClinicalTrials.gov registry entry for NCT02375451 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radioiodine is the first listed.
NCT02375451 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02375451 about?
NCT02375451 is a clinical study titled "Effect of Childhood Radioiodine Therapy on Salivary Function". Radioiodine (I-131) therapy for thyroid disease is known to decrease salivary function in adult patients. The impact of pediatric I-131 exposure on salivary function is unknown. The investigators goals are to answer this question by measuring salivary gland function before and after I-131 administra...
What is the current status of trial NCT02375451?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2014-09. Estimated completion is 2016-09.
What conditions does trial NCT02375451 study?
This clinical trial studies the following conditions: Thyroid Cancer, Xerostomia, Hyperthyroidism.
What interventions are being tested in trial NCT02375451?
The interventions under investigation include: Radioiodine (OTHER).
Who is sponsoring clinical trial NCT02375451?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02375451 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.